Efficacy and safety of nilotinib 800 mg daily in early chronic phase Ph+ chronic myeloid leukemia: Results of a phase II trial at 2 years. Background: BCR-ABL transcript levels have been reported to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback